Principal Investigator
Justin Watts
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20251348
Clinical Trial Summary
Olutasidenib combined with co-targeted therapy in relapsed or refractory IDH1-mutated myeloid malignancies harboring activated signaling pathway mutations
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647